- Home
- PAM vs ACLX Comparison
PAM vs ACLX Comparison
Compare PAM & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$68.70
Company Overview
Basic Information| Metric | PAM | ACLX |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PAM | ACLX |
|---|---|---|
| Price | $90.06 | $68.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $92.75 | ★ $115.50 |
| AVG Volume (30 Days) | 225.0K | ★ 1.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,926,000,000.00 | $35,898,000.00 |
| Revenue This Year | $136,919.08 | N/A |
| Revenue Next Year | $36.38 | $302.49 |
| P/E Ratio | $15.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.95 | $47.86 |
| 52 Week High | $97.55 | $94.07 |
Technical Indicators
Market Signals| Indicator | PAM | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 33.01 |
| Support Level | $89.01 | $66.00 |
| Resistance Level | $91.02 | $75.03 |
| Average True Range (ATR) | 3.52 | 5.23 |
| MACD | -0.46 | -1.69 |
| Stochastic Oscillator | 66.81 | 12.96 |
Price Performance
Historical Comparison PAM
ACLX
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.